KF
AGIO icon

Krilogy Financial’s Agios Pharmaceuticals AGIO Stock Holding History

Krilogy Financial’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-100
Closed -$7K – 765
2017
Q3 		$7K Hold
100
– – ﹤0.01% 611
2017
Q2 		$5K Buy
+100
New +$5.11K ﹤0.01% 586

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Krilogy Financial's AGIO Position: Q4 2017 in Review

Krilogy Financial sold out of Agios Pharmaceuticals (AGIO) in Q4 2017, closing a stake of 100 shares — an estimated $7K sold.

Krilogy Financial first reported a position in AGIO in Q2 2017 and held it in 2 quarters. The position peaked at $7K in Q3 2017. 178 funds tracked by Wall St. Rank hold AGIO as of Q4 2017.

  • Krilogy Financial reported no remaining Agios Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Krilogy Financial sold 100 Agios Pharmaceuticals shares in Q4 2017, an estimated $7K.
  • Krilogy Financial first reported a position in Agios Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Krilogy Financial's Agios Pharmaceuticals position peaked at $7K in Q3 2017.
  • 178 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2017.

Based on Krilogy Financial's 13F filing for Q4 2017, filed 14 Feb 2018.